Evidence map›Paper›PMID 26055340›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2015

Hepatic arterial infusion plus systemic chemotherapy as third-line or later treatment in colorectal liver metastases.

W-G Qiang, L-R Shi, X-D Li, Q-Q Wu, J-M Zhao, L-J Chen, Y Yang, J Wu, M Ji, C-P Wu

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

W-G QiangDepartment of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, China.
L-R ShiDepartment of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, China.
X-D LiDepartment of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, China.
Q-Q WuDepartment of Radiation Oncology, Changzhou Cancer Hospital of Soochow University, Changzhou, China.
J-M ZhaoDepartment of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, China.
L-J ChenDepartment of Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Y YangDepartment of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, China.
J WuDepartment of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, China.
M JiDepartment of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, China.
C-P WuDepartment of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, China. wcpjjt@163.com.
Soochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundsThe present study aimed to evaluate benefit of hepatic arterial infusion chemotherapy (HAI) combined with systemic chemotherapy (SCT) for patients with colorectal liver metastases (CLMs) in a palliative setting.

methodsThis was a retrospective single-center study including 43 consecutive patients with CLM after failure of standard SCT. Among them, 20 (47 %) patients underwent HAI combined with SCT (Group A) and 23 historical control patients who had received SCT with or without targeted agent treatment (Group B).

resultsThe two groups had similar characteristics. Compared with SCT alone, HAI combined with SCT prolonged survival (median 19.8 vs. 9.0 months; P = 0.045). Median hepatic progression-free survival was significantly longer for HAI combined with SCT vs. SCT alone (median 8.1 vs. 4.7 months; P = 0.027), as were response rates (25 and 0 %; P = 0.038) and progression-free survival (median 5.7 vs. 3.0 months; P = 0.02). Three patients (15 %) achieved conversion to potentially curative surgery. Grade 3/4 toxicities for Group A and Group B were neutropenia (5 and 8.7 %, respectively), anemia (5 and 0 %, respectively), and hyperbilirubinemia (0 and 4.3 %, respectively). Other complications were mostly grade 1 or 2.

conclusionsHAI combined with SCT treatment can improve overall survival compared with SCT alone in highly advanced CLM refractory to intravenous chemotherapy.

Indexed as

AdenocarcinomaAdultAgedAged, 80 and overAntineoplastic AgentsColorectal NeoplasmsDisease-Free SurvivalFemaleHepatic ArteryHumansInfusions, Intra-ArterialKaplan-Meier EstimateLiver NeoplasmsMaleMiddle AgedRetrospective StudiesAntineoplastic AgentsColorectal liver metastasesHepatic arterial infusionSystemic chemotherapy

Identifiers

PMID26055340
OpenAlexW642356947

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.